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Introduction
COPD is a complex inflammatory airway disease charac-
terized by airflow limitation that is not fully reversible.
The mechanisms and mediators that drive the induction
and progression of chronic inflammation, emphysema
and altered lung function are poorly understood. Cur-
rent treatments have limited efficacy in COPD and there
is a clear need for new therapies that can prevent the
induction and progression of COPD. Animal modeling
systems that accurately reflect disease pathophysiology
continue to be essential to the development of new
therapies.
Aim
To develop preclinical in vivo models that recapitulate
many of the features of COPD.
Materials and methods
Mice were exposed to cigarette smoke (CS) for up to 6
months and the hallmarks of COPD investigated. In
some experiments, CS-exposed mice were infected with
influenza A virus (H3N1, Mem71 strain) to mimic acute
exacerbations of COPD (AECOPD).
Results
We have developed preclinical murine models of COPD
that replicate key clinical traits observed in human dis-
ease, including BAL and lung inflammation, induction
of various cytokines/chemokines/proteases, increased
oxidative stress, goblet cell hyperplasia, emphysema and
lung function deterioration. These models have identi-
fied novel pathways that control leukocyte accumulation
and lung damage. When modeling systemic comorbid-
ities of COPD, we found that mice exposed to CS had
reduced body weight, fat mass, hind limb skeletal mus-
cles mass, grip strength and aerobic endurance. CS
altered the mRNA expression of a number of genes
associated with the regulation of skeletal muscle mass
including insulin-like growth factor-I, atrogin-1 and IL-
6. Moreover, the levels of neuropeptide Y were reduced
in CS-exposed mice. Compared to CS or influenza
alone, mice exposed to CS and then influenza had more
BAL inflammation, lung virus titres, altered profiles of
key cytokines, worse lung pathology and more virus-spe-
cific, activated CD8+ T lymphocytes in BAL. CS expo-
sure caused temporary weight loss and when smoking
ceased after viral infection, CS and influenza mice
regained significantly less weight than CS alone mice.
Conclusions
Using these preclinical in vivo models of COPD, we
have identified key mediators which initiate and drive
COPD. Understanding the neuromolecular and systemic
processes that lead to loss of body weight in smokers
may provide novel intervention points for improving
cessation therapy and may also contribute to under-
standing wasting syndromes in smoking-related lung
diseases. With respect to exacerbations of COPD, it is
clear that CS exposure worsens the host response to
influenza virus.
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